Platelet-rich plasma, a promising adjunctive treatment for vitiligo: A case report

Yin, Lu; Adotama, Prince; Svigos, Katerina; Gutiérrez, Daniel; Sicco, Kristen Lo

doi:10.1016/j.jdcr.2020.09.021

Cited by 5 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Growth factors that stimulate keratinocyte and fibroblast proliferation and improve their interaction with melanocytes to make them stable 12 . These multiple factors lead to the migration of melanocytes from peri‐lesional skin, thus allowing repigmentation 13–16 . Basic fibroblast growth factor (b‐FGF) enhances melanocyte migration, keratinocyte, and fibroblast proliferation 8 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of autologous platelet‐rich plasma in the treatment of vitiligo: A 10‐patient prospective study

Rekik

Mseddi

Kammoun

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Introduction Vitiligo is an autoimmune disorder characterized by loss of epidermal melanocytes. It has cosmetic and psychosocial impact. The objective of this paper is to evaluate the interest of platelet‐rich‐plasma in the treatment of vitiligo. Material and methods We conducted a prospective study between January 2019 and September 2021. Results Our descriptive study included 10 patients followed‐up for vitiligo refractory to conventional therapies. The mean age was 36.2 years. Sex ratio was 0.25. Prior to platelet‐rich‐plasma treatment, vitiligo was stable in all cases. The mean number of platelet‐rich‐plasma sessions received by our patients was 2.6 (1–6). A visible improvement of lesions was obtained after a mean of 1.5 sessions. 40% of patients had obtained repigmentation of more than 50% for at least one lesion. An improvement of more than 75% (grade 4) was noted in 2 cases after a mean duration of 5.5 sessions. 40% of patients had obtained repigmentation of more than 50% for at least one lesion. A percentage of improvement between 50 and 74% (grade 3) was obtained for 2 patients. Four patients had an improvement of less than 25% (grade 1) after a mean of 1.75 sessions. There was no recurrence of depigmentation after a mean follow‐up of 6 months (1 to 24 months). Conclusion Our series proves the benefit of platelet‐rich‐plasma in the treatment of vitiligo. It is a safe and promising option for stable lesions in different body sites with few side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

“…12 These multiple factors lead to the migration of melanocytes from peri-lesional skin, thus allowing repigmentation. [13][14][15][16] Basic fibroblast growth factor (b-FGF) enhances melanocyte migration, keratinocyte, and fibroblast proliferation. 8 The response for TGFβ is better if vitiligo is stable.…”

Section: Prp Treatment Can Improve Vitiligo Throughmentioning

confidence: 99%

Efficacy of autologous platelet‐rich plasma in the treatment of vitiligo: A 10‐patient prospective study

Rekik

Mseddi

Kammoun

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…9 Platelet-rich plasma (PRP) consists of a high number of platelets and high concentrations of growth factors. 10 PRP was recently demonstrated to stimulate the differentiation, proliferation, and maturation of melanocytes and keratinocytes, 11 which participate in the pathogenesis of vitiligo.…”

Section: Introductionmentioning

confidence: 99%

Meta-analysis of the efficacy of adding platelet-rich plasma to 308-nm excimer laser for patients with vitiligo

Tang

et al. 2022

J Int Med Res

View full text Add to dashboard Cite

Objective Platelet-rich plasma (PRP) is a novel treatment option for vitiligo. PRP has been reported to be effective in combination with 308-nm excimer laser therapy, but there is no consensus on their combination use. Therefore, this meta-analysis assessed the efficacy and safety of the combination regimen in patients with vitiligo compared with laser therapy alone. Methods The meta-analysis was performed by searching PubMed, EMBASE, Web of Science, Cochrane Library, Chinese National Knowledge Infrastructure, and WanFang to identify relevant publications published through 1 February 2022. Results Six studies involving 302 patients were included. Compared with phototherapy alone, combination treatment with PRP and 308-nm excimer laser therapy significantly improved the total response rate and reduced the no response rate. Additionally, the proportions of patients with repigmentation rates of ≥75%, ≥50%, and ≥25% were significantly higher in the combination group than in the monotherapy group. In addition, the rates of adverse events for combination therapy were comparable to those for laser therapy alone, and the recurrence rates were low. Conclusions This meta-analysis provided evidence supporting the combined use of PRP and 308-nm excimer laser therapy as a valuable treatment modality for patients with vitiligo based on its superiority to monotherapy.

show abstract

“…New uses of topical or intradermal PRP in the field of dermatology are emerging every day, one of these is vitiligo. Growth factors and cytokines within the PRP are postulated to stimulate the differentiation, proliferation, and maturation of melanocytes and keratinocytes, resulting in skin repigmentation 7 …”

Section: Introductionmentioning

confidence: 99%

“…Growth factors and cytokines within the PRP are postulated to stimulate the differentiation, proliferation, and maturation of melanocytes and keratinocytes, resulting in skin repigmentation. 7 Various clinical studies investigated the effectiveness of PRP in the treatment for vitiligo, either alone or in combination with NB-UVB, excimer laser, fractional CO 2 laser, vitamin D, or non-cultured epidermal cell suspension (NCES) with conflicting results. [8][9][10][11][12][13][14][15][16][17][18] Regarding the combination of PRP with phototherapeutic modalities, 2 studies investigated the value of adding PRP to NB-UVB.…”

mentioning

confidence: 99%

Comparison between 308‐nm excimer light alone versus 308‐nm excimer light and platelet‐rich plasma in the treatment for localized vitiligo

Elsaadany

El‐Khalawany

Elshahid

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Vitiligo affects 0.5-1% of the general population and represents the commonest depigmenting skin disease. 1 Therapeutic options available for vitiligo include topical and systemic immune-modulatory agents, surgery, cosmetic camouflage, and photo[chemo]therapy. Conventional phototherapies include psoralen and ultraviolet (UV) A (PUVA), broadband UVB (BB-UVB, 290-320 nm), and narrowband UVB (NB-UVB, 311-313 nm). 2 Targeted phototherapy uses special delivery mechanisms to target only the affected skin such as hand-held NB-UVB delivery systems, excimer laser, and excimer lamp. Two major types of machines utilize a xenon-chloride (XeCl) gas mixture to emit monochromatic excimer light (MEL, 308 nm) with almost equivalent efficacy: the

show abstract

Platelet-rich plasma, a promising adjunctive treatment for vitiligo: A case report

Cited by 5 publications

References 10 publications

Efficacy of autologous platelet‐rich plasma in the treatment of vitiligo: A 10‐patient prospective study

Efficacy of autologous platelet‐rich plasma in the treatment of vitiligo: A 10‐patient prospective study

Meta-analysis of the efficacy of adding platelet-rich plasma to 308-nm excimer laser for patients with vitiligo

Comparison between 308‐nm excimer light alone versus 308‐nm excimer light and platelet‐rich plasma in the treatment for localized vitiligo

Contact Info

Product

Resources

About